Information on Alzheimer’s Disease

Alzheimer’s disease is an irreversible brain disease that affects memory, thinking, and the ability to complete daily tasks. Approximately 5 million people in the U.S. have Alzheimer’s disease. It is the most common cause of dementia and accounts for 60 to 80% of all dementia cases. It is estimated that there are approximately 44 million people worldwide living with Alzheimer’s disease or a related form of dementia. There is currently no cure for Alzheimer’s, and the disease is typically fatal within 10 years of onset. Therefore, our inventions will be a game changer because not only it will provide an effective drug delivery strategy, it will also provide a treatment strategy for Alzheimer’s disease.
More than 1 in 9 people (11.3%) age 65 and older has Alzheimer’s disease. The percentage of people with Alzheimer’s dementia increases with age: 5.3% of people age 65 to 74, 13.8% of people age 75 to 84, and 34.6% of people age 85 and older have Alzheimer’s dementia. According to the World Health Organization, an estimated 50 million people worldwide currently have dementia, and there are nearly 10 million new cases every year; Alzheimer disease affects about 60-70% of them.
The global market for Alzheimer’s disease expected to attain $25 billion by 2027, growing at a staggering CAGR of 17.5% over the forecast period, driven by rapidly ageing population, increasing prevalence of AD, coupled with technological advancements in diagnostics and biomarkers.

Low blood flow starts In MCI patient and increases in AD

Decreasing glucose metabolism from MCI to AD patient’s brain


1. E.J. Mufson, L. Mahady, D. Waters, S.E. Counts, S.E. Perez, S.T. DeKosky, S.D. Ginsberg, M.D. Ikonomovic, S.W. Scheff, L.I. Binder, Hippocampal plasticity during the progression of Alzheimer’s disease, Neuroscience, Volume 309, 2015, Pages 51-67,ISSN 0306-4522,
2. A.E. Leeuwis et al. / Alzheimer’s & Dementia – (2016) 1-10.
3. Memory test and PET scans detect early signs of Alzheimer’s.

© Copyright 2022 - AmritaGen, Inc